高榕创投
@gaorong
创造美好生活
Fube Biotech Closes A++ Round to Pioneer CNS Drug R&D Through Homegrown Innovation
Accelerate multiple novel neurological drug candidates into clinical trials.
Rongbao · January | E-commerce and Retail Players Build Out Origin-Region Supply Chains; Multiple Chip, AI, and Enterprise Service Firms Close New Funding Rounds
Discover and accompany creators of a beautiful life.
Hyperparameter Closes $30 Million Series A+ Round to Accelerate Game AI Expansion
Dedicated to transforming how game content is produced through artificial intelligence.
Galixir's Chengtao Li: Finding the "Key" to Curing Disease with AI in the Universe of Compounds | Rong Talk --- In the vast "universe" of chemical compounds, finding the molecule that can precisely target a disease is like searching for a needle in a haystack — except the haystack contains more stars than there are in the Milky Way. This is where Galixir comes in. Founded in 2019, Galixir is an AI-driven drug discovery company that uses artificial intelligence to navigate the astronomical complexity of molecular space. At its helm is Chengtao Li, a Tsinghua University PhD who spent years at MIT's Computer Science and Artificial Intelligence Laboratory (CSAIL) before returning to China to build what he calls "a new kind of pharmaceutical R&D engine." "The traditional drug discovery process is incredibly inefficient," Li tells us in a wide-ranging conversation at the company's Beijing headquarters. "You're talking about 10 to 15 years and $2-3 billion to bring a single drug to market. And the failure rate is brutal. We think AI can fundamentally change that equation." Galixir's approach centers on what Li describes as "generative chemistry" — using deep learning models to design novel molecules from scratch, rather than merely screening existing compound libraries
How artificial intelligence technology is accelerating drug discovery and development.
Xinhuazhang, an EDA company, announced the completion of its Series A+ funding round to accelerate R&D progress on EDA 2.0.
Building EDA 2.0 technology for a digital society, defining an intelligent future from the chip up.
Shexu Technology Raises Tens of Millions of RMB in Angel Round to Build Industrial Intelligent Design and Manufacturing Cloud Platform
AI + SaaS, making industrial design smarter.
Gaorong Bulletin · December | Multiple Gaorong Ventures Portfolio Companies Secure New Funding in Chips, Robotics, AI Drug Discovery, New Brands, and Other Sectors
Stepping into 2021.
General-purpose intelligent robotics company Flexiv completes over $100 million Series B funding round
Gaorong Ventures led the investment in Flexiv in early 2019 and continued to increase its stake in subsequent funding rounds.
Hanwei Microelectronics Closes Pre-A Strategic Round, Low-Power Team Targets UWB High-Precision Positioning Market
UWB technology will become an important foundational technology for the era of the intelligent Internet of Everything.
Galixir Announces Tens of Millions of Dollars in Funding, Using "AI+" to Break Through Bottlenecks in Drug Discovery
Gaorong Ventures led Galixir's angel round and continued to increase its stake in subsequent funding rounds.
Huatai United Securities' Jiang Yu: How Innovative Companies Can Navigate the Path to Listing in the Registration-Based Era | Ronghui
How Can Innovative Companies Seize the Registration-Based IPO Opportunity and Make the Right Capital Strategy Choices?
EDA Technology Breakthrough Xinhuazhang Announces Over RMB 200 Million Series A Funding Round, Led by Gaorong Ventures
Defining the future of intelligence, from the chip up.